by Ian Cooper | Oct 27, 2015 | Uncategorized
On September 27, I recommended a buy on the Rite Aid (RAD) January 2016 7 call up to 80 cents. Hearing that some of you bought at just 50 cents, you’ll be happy to know that the call last traded at $1.85. That’s a gain of 270% in less than a month. That gain is thanks...
by Ian Cooper | Oct 27, 2015 | Uncategorized
Shares of AbbVie (ABBV) plummeted the other day after the FDA warned that the company’s hepatitis C treatments – Viekira Pak and Technivie – could cause serious injury to the liver mostly in patients with underlying advanced liver disease. In the warning, the FDA...
by ADRIAN MANZ | Oct 25, 2015 | Uncategorized
On Monday October 26, 2015 we will close positions that were opened on September 27, 2015 for a .44% gain. Those positions are as follows: Ticker Return % Start Price End Price KOP -11.02 21.50 19.13 UIS 8.54 13.11 14.23 CLS -10.53 12.73 11.39 SANM 1.06 20.77 20.99...
by Ian Cooper | Oct 19, 2015 | Uncategorized
I think it’s great that Oprah Winfrey took a 10% stake in Weight Watchers… The company – 75% off its highs – needed the news. But it’ll take more than the Oprah Effect to keep this stock moving higher. Poor sales, increased competition, and new weight tools could...
by Ian Cooper | Oct 14, 2015 | Uncategorized
Shares of Phillip Morris (PM) are challenging overhead resistance just above $85 a share. Since early 2013, the stock has failed at this point about eight times. I’m expecting more of the same this time. RSI, MACD and MFI all tell us this stock is overbought… and...
by Ian Cooper | Oct 12, 2015 | Uncategorized
Historically, we’ve done quite well with Coke… Using nothing more than Bollinger Bands, RSI, MACD, W%R, MFI and candlesticks, we’re able to predict pivots off oversold and overbought conditions up to 85% of the time. Nowadays, as Coke over-extends to $42 a share, our...
by Ian Cooper | Oct 12, 2015 | Uncategorized
In recent weeks, shares of Amicus Therapeutics (FOLD) plunged from $15 to $6 on news the FDA is asked for more information on its treatment for Fabry disease, an inherited disorder stemming from a buildup of a fat in the body called globotriaosylceramide. It means...
by Ian Cooper | Oct 9, 2015 | Uncategorized
As Aflac becomes technically over-extended, its time to book gains… On September 10, we recommended a buy on the stock [$57.10 entry], the January 57.50 call [$2.90 entry] and the January 60 call [$1.85 entry]. At the moment, the stock trades at $60.83. That gives us...
by Ian Cooper | Oct 9, 2015 | Uncategorized
Since recommending the InterOil (IOC) stock and November 35 calls at $35 and $4.45, respectively, the stock has moved to just under $39 a share. That gives us an 11% gain on the stock, and a 24% gain on the calls, which now trades with a bid-ask of $5.25 x $6.35....
by Ian Cooper | Oct 7, 2015 | Uncategorized
Over the last few days, shares of DuPont (DD) have popped about 15% on news of the CEO departure. But unless there’s a significant change – and upside – in the commodities sector, I see very little to get excited about with this stock. Plus, the company just cut is...
